Pneumonitis after radiotherapy for lung cancer (PARALUC): an interventional study to create a symptom-based scoring system for identification of patients developing radiation pneumonitis

Rades, Dirk; Werner, Elisa; Glatzel, Esther; Eggert, M. J.; Olbrich, Denise; Tvilsted, Soeren; Bohnet, Sabine

doi:10.1186/s12885-020-07291-5

Cited by 8 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2022 [ 32 ] ePRO (QoL) during and 4 weeks after RT (MyHospital, developed by MedWare, Odense, Denmark) Single arm 40 Prostate and cervical cancer receiving pelvic RT (curative) Feasible, high adherence to weekly self-reporting, time spent acceptable No Rades et al. 2020 [ 14 ] and 2022 [ 65 ] Assessment of patient-reported outcome (symptoms of pneumonitis, QoL, other adverse effects) to detect a radiation pneumonitis during and after RT (PARALUC) Prospective, single arm 57 Lung cancer patients receiving RT/RCT (curative) c Patient satisfaction with score and app (prototype) was very high. The developed score to detect pneumonitis showed excellent diagnostic accuracy No Sprave et al.…”

Section: Resultsmentioning

confidence: 99%

“…This included recording of all types of RT-related side effects and symptoms like pain, general performance, and quality of life. Sometimes validated questionnaires like the EORTC (European Organisation for Research and Treatment of Cancer) QLQ C30 were used [ 13 , 14 , 20 – 22 ]; in other studies, this was not stated in detail. Side effects were usually evaluated concerning the irradiated area, e.g., swallowing difficulties, dryness of mouth, skin reaction, and mucositis in head and neck cancer patients.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Mobile applications in radiation oncology—current choices and future potentials

et al. 2023

Self Cite

View full text Add to dashboard Cite

Purpose To review existing scientific literature on mobile applications (apps) in the field of radiation oncology and to evaluate characteristics of commercially available apps across different platforms. Methods A systematic review of the literature for publications presenting apps in the field of radiation oncology was carried out using the PubMed database, Cochrane library, Google Scholar, and annual meetings of major radiation oncology societies. Additionally, the two major marketplaces for apps, App Store and Play Store, were searched for available radiation oncology apps for patients and health care professionals (HCP). Results A total of 38 original publications which met the inclusion criteria were identified. Within those publications, 32 apps were developed for patients and 6 for HCP. The vast majority of patient apps focused on documenting electronic patient-reported outcomes (ePROs). In the two major marketplaces, 26 apps were found, mainly supporting HCP with dose calculations. Conclusion Apps used in (and for) scientific research in radiation oncology are rarely available for patients and HCP in common marketplaces.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Mobile applications in radiation oncology—current choices and future potentials

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…For adequate personalized counseling, identifying risk factors regarding the probability of grade ≥2 ARD and RP is valuable. RP can be serious and difficult to diagnose and often occurs several weeks or months following RT (35,36). Therefore, it is important to identify patients who are at risk of developing grade ≥2 RP.…”

Section: Discussionmentioning

confidence: 99%

Radiation Dermatitis and Pneumonitis in Patients Irradiated for Breast Cancer

EGGERT,

YU,

RADES

2023

In Vivo

View full text Add to dashboard Cite

Background/Aim: Adjuvant radiotherapy (RT) for breast cancer can be associated with acute dermatitis (ARD) and pneumonitis (RP). Prevalence and risk factors were characterized. Patients and Methods: This study included 489 breast cancer patients receiving adjuvant RT with conventional fractionation (CF) ± sequential or simultaneous integrated boost, or hypo-fractionation ± sequential boost. RTregimen and 15 characteristics were investigated for grade ≥2 ARD and RP. Results: Prevalence of grade ≥2 ARD and RP was 25.3% and 2.5%, respectively. On univariate analyses, ARD was significantly associated with CF and radiation boost (p<0.0001), age ≤60 years (p=0.008), and systemic treatment (p=0.002). On multivariate analysis, and age (p=0.009) were associated with ARD. Chronic inflammatory disease was significantly associated with RP on univariate (p=0.007) and multivariate (p=0.016) analyses. Conclusion: Risk factors for grade ≥2 ARD and RP were determined that may help identify patients who require closer monitoring during and after RT.Breast cancer is the most common cancer type in females in Western countries (1, 2). Many of these women with nonmetastatic disease receive breast conserving surgery or mastectomy followed by local or loco-regional irradiation (3,4). Adjuvant radiotherapy (RT) may be associated with adverse events including acute radiation dermatitis (ARD) and radiation pneumonitis (RP) (5,6). ARD was reported to have a negative impact on the patients' quality of life, and RP can even be fatal (7, 8). In the literature, the prevalence of clinically relevant grade ≥2 ARD ranges between 3% and 76%, with higher rates in patients treated with conventional fractionation (CF) than in patients receiving hypofractionation (HF) (9-26). ARD usually develops during the second to third week of radiotherapy, becomes more severe during the further RT-course and possibly the first post-RT week, and disappears a few weeks after completion of RT (5). In contrast, RP is considered a subacute effect of RT, which often develops only several weeks or months following RT (6). The prevalence of RP after RT of breast cancer ranges between 0.8% and 19. 6% (6, 10, 27-33). Considering the comparably wide ranges regarding the prevalence of ARD and RP, it becomes obvious that additional studies are required to more precisely define the prevalence of these two RT-related side effects in breast cancer patients. Our present study evaluated the prevalence in a cohort of breast cancer patients irradiated between 2016 and 2019. Moreover, it aimed to determine risk factors for ARD and RP, in order to contribute to early identification of patients at risk who would benefit from closer monitoring of adverse events during and after the RT-course. Patients and MethodsThe present retrospective study investigated grade ≥2 ARD and grade ≥2 RP in 489 female breast cancer patients treated with adjuvant radiotherapy between 2016 and 2019. The original study protocol and an amendment were approved by the ethics committee of the University of Lü...

show abstract

“…Radiation pneumonitis (RP) is an inflammatory response caused by damage to normal lung tissue in the radiation field after a variety of malignant tumors, including esophageal cancer, are damaged [4]. As the most common adverse reaction of chest radiotherapy, RP also limits the prescribed dose given by clinicians, which affects the treatment effect and patient prognosis.…”

Section: Introductionmentioning

confidence: 99%

Serum MMP-9 and SAA in the Diagnosis of Severe Pneumonia Caused by Radiotherapy of Esophageal Cancer

Zhou

Liu

2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To explore the relationship and diagnostic value of serum MMP-9 and SAA in severe pneumonia (sCAP) caused by radiotherapy of esophageal cancer. Methods. A total of 144 esophageal cancer patients who underwent radiotherapy in our hospital from April 2016 to February 2018 were collected. Among them, 58 patients without radiation pneumonitis (RP) were in the control group, 49 patients with grade 1∼2 RP were in the radiation group, and 37 patients with sCAP were in the severe group. The levels of serum MMP-9 and SAA in every group of patients were detected. The ROC curve was used to determine the diagnostic value of serum MMP-9 and SAA in the diagnosis of RP and sCAP. The correlation between serum MMP-9 and SAA and the patient’s lung function indexes was analyzed, and the logistic single-factor and multivariate analyses were performed to analyze the factors of sCAP in esophageal cancer radiotherapy. Results. PaO2, FVC, and FEV1 decreased in RP and sCAP, and PaCO2, white blood cells, serum MMP-9, and SAA levels increased ( P < 0.05 ); serum MMP-9 and SAA were negatively correlated with lung function ( P < 0.05 ); the AUC of serum MMP-9 and SAA in RP was 0.833 and 0.823, respectively, and the AUC of the two combined diagnosis of RP was 0.919. The AUC of serum MMP-9 and SAA in sCAP was 0.809 and 0.797, respectively, and the AUC of both combined diagnosis of sCAP was 0.873; logistics multivariate analysis found that serum MMP-9, serum SAA, double lung V5, and V20 were independent risk factors for sCAP caused by radiotherapy for esophageal cancer ( P < 0.05 ). Conclusion. Serum MMP-9 and SAA increase in RP and sCAP and are negatively correlated with lung function in patients with pneumonia. They are independent risk factors for severe pneumonia caused by radiotherapy of esophageal cancer and have good diagnostic value.

show abstract

Pneumonitis after radiotherapy for lung cancer (PARALUC): an interventional study to create a symptom-based scoring system for identification of patients developing radiation pneumonitis

Cited by 8 publications

References 20 publications

Mobile applications in radiation oncology—current choices and future potentials

Mobile applications in radiation oncology—current choices and future potentials

Radiation Dermatitis and Pneumonitis in Patients Irradiated for Breast Cancer

Serum MMP-9 and SAA in the Diagnosis of Severe Pneumonia Caused by Radiotherapy of Esophageal Cancer

Contact Info

Product

Resources

About